Cadinha & Co. LLC Has $1.68 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Cadinha & Co. LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,209 shares of the medical research company’s stock after purchasing an additional 32 shares during the quarter. Cadinha & Co. LLC’s holdings in Amgen were worth $1,678,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Nomura Holdings Inc. bought a new position in Amgen in the 4th quarter worth approximately $3,104,000. MGO One Seven LLC increased its holdings in Amgen by 4.4% during the fourth quarter. MGO One Seven LLC now owns 6,363 shares of the medical research company’s stock valued at $1,833,000 after buying an additional 268 shares during the last quarter. Northwest Wealth Management LLC bought a new position in shares of Amgen in the fourth quarter worth approximately $242,000. Creative Planning boosted its position in shares of Amgen by 3.0% during the fourth quarter. Creative Planning now owns 162,429 shares of the medical research company’s stock worth $46,783,000 after acquiring an additional 4,720 shares during the last quarter. Finally, Vivaldi Capital Management LP increased its stake in Amgen by 22.8% in the 4th quarter. Vivaldi Capital Management LP now owns 1,958 shares of the medical research company’s stock worth $569,000 after buying an additional 363 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AMGN shares. TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $362.00 price target on shares of Amgen in a report on Thursday, September 26th. Argus upped their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Oppenheimer restated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $326.30.

Amgen Trading Down 0.6 %

AMGN stock traded down $2.03 during midday trading on Thursday, reaching $320.38. The stock had a trading volume of 306,347 shares, compared to its average volume of 2,466,407. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The firm has a market cap of $171.86 billion, a price-to-earnings ratio of 46.06, a PEG ratio of 2.98 and a beta of 0.61. The business has a fifty day simple moving average of $326.46 and a two-hundred day simple moving average of $310.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the company earned $5.00 earnings per share. Amgen’s quarterly revenue was up 20.1% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.81%. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.